ZimVie price target raised to $16 from $13 at Barclays

Barclays raised the firm’s price target on ZimVie to $16 from $13 and keeps an Underweight rating on the shares. The analyst says that while ZimVie reacted positively to management’s planned divestiture of its spine business announced in December, the company’s continuing operations are now concentrated in the “sluggish market” for dental implants.